Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1433-7339
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma ; volume:30 ; number:7 ; day:1 ; month:4 ; year:2022 ; pages:5859-5869 ; date:7.2022
Supportive care in cancer ; 30, Heft 7 (1.4.2022), 5859-5869, 7.2022

Creator
Nathwani, Nitya
Bell, Jill
Cherepanov, Dasha
Sowell, France Ginchereau
Shah, Rachel
McCarrier, Kelly
Hari, Parameswaran
Contributor
SpringerLink (Online service)

DOI
10.1007/s00520-022-06979-7
URN
urn:nbn:de:101:1-2022072819545011993836
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nathwani, Nitya
  • Bell, Jill
  • Cherepanov, Dasha
  • Sowell, France Ginchereau
  • Shah, Rachel
  • McCarrier, Kelly
  • Hari, Parameswaran
  • SpringerLink (Online service)

Other Objects (12)

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

Related objects